Natalizumab biosimilar - GENERIUM Pharmaceuticals
Alternative Names: GNR 093Latest Information Update: 22 Apr 2024
At a glance
- Originator GENERIUM Pharmaceuticals
- Class Anti-inflammatories; Antiepileptic drugs; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Multiple sclerosis
Most Recent Events
- 21 Mar 2024 Phase-II/III clinical trials in Multiple sclerosis in Russia (IV), prior to March 2024 (Generium Pharmaceuticals pipeline, March 2024)